Embecta sued for securities fraud after 57% stock crash

Embecta faces a securities fraud class action after its stock plunged 57.8 percent on May 5 following a Q2 guidance miss.

The complaint, filed by Bleichmar Fonti & Auld LLP in the U.S. District Court for the District of New Jersey, alleges Embecta touted the "resilience" of its insulin pen portfolio while facing significant competition and "overall market softness for insulin pens and pen needles."

On May 5, Embecta reported Q2 2026 results below guidance, citing "share loss within its pen needle product category, most of which was from a single customer," and cut its quarterly dividend from $0.15 to $0.01 per share. The stock fell $5.35, or 57.8 percent, from $9.25 to $3.90 per share.

Investors have until August 17 to seek lead plaintiff appointment in the case, captioned Apitz-Grossman v. Embecta Corp., No. 26-cv-07217. The suit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of purchasers of Embecta common stock during the class period from November 25, 2025 to May 4, 2026.

The complaint alleges Embecta's guidance was misleading and unattainable, and that the company failed to disclose that segment weakness in the U.S. pen needle market would disrupt its revenue guidance and Q2 results. The company had stated that "prescriptions for insulin pens have been showing a slight positive trend . . . just exemplifying the resilience of this product portfolio." Embecta also admitted on its earnings call that it had "now begun to see a decline [for insulin pens] maybe more pronounced in the most recent quarter that we reported."

Embecta, a medical device company producing insulin pens for diabetes patients, had described its pen needle business as "incredibly resolute" weeks before missing expectations and cutting full-year 2026 guidance, according to the complaint. The company also announced "a review of our cost structure and organizational footprint" alongside the results.

BFA has recovered over $900 million in value from Tesla Inc.'s board of directors and $420 million from Teva Pharmaceutical Industries Ltd. The firm said all representation is on a contingency fee basis with no cost to shareholders, and that it will seek court approval for any potential fees and expenses. Several other firms, including the Law Offices of Howard G. Smith and Bragar Eagel & Squire, have also announced investor actions against Embecta with the same August 17 lead plaintiff deadline.

The 57.8 percent single-day decline puts Embecta's stock at its lowest level since the company was spun off from Becton Dickinson in 2022. The dividend cut from $0.15 to $0.01 per share shows management's urgency to preserve cash as it reviews its cost structure and organizational footprint. Investors will watch for further disclosures from the cost review and any additional legal filings before the August 17 lead plaintiff deadline.

This article is for informational purposes only and does not constitute investment advice.